A practical reference on NAMPT: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-03 and is reviewed periodically as new material appears.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
Trace amounts of NMN have been reported in certain plant foods, including edamame, avocado, broccoli, cucumber, and cabbage. Reported concentrations vary widely because analytical methods differ and food matrices complicate extraction. Endogenous production in cells is generally considered more quantitatively important than dietary intake, though precise human turnover rates are difficult to establish. Commercial NMN for research or consumer products is commonly made through enzymatic synthesis or chemical phosphorylation routes. Regulatory classification differs by country; in some jurisdictions NMN is sold as a supplement, while in others it is treated as a novel food ingredient or restricted substance.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. As an intermediate in the NAD+ salvage pathway, NMN is converted to nicotinamide adenine dinucleotide, a coenzyme central to cellular redox reactions. NAD+ also serves as a substrate for enzymes involved in DNA repair, stress responses, and metabolic regulation. The compound is therefore part of normal cellular biochemistry rather than an exclusively synthetic molecule.
| Property | Value | Notes |
|---|---|---|
| Chemical name | beta-Nicotinamide mononucleotide | Free acid and salt forms share the core structure. |
| Molecular formula | C11H15N2O8P | Calculated for the free acid; salt forms add counterions. |
| Molar mass | 334.22 g/mol | Approximate value for the free acid form. |
| Appearance | White to off-white powder | Color and texture can vary with purity and salt form. |
| Solubility | Water-soluble | Typically soluble in aqueous media; less soluble in nonpolar solvents. |
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
=== Derivatives === HMF itself has few applications. It can however be converted into other more useful compounds. Of these the most important is 2,5-furandicarboxylic acid, which has been proposed as a replacement for terephthalic acid in the production of polyesters. HMF can be converted to 2,5-dimethylfuran (DMF), a liquid that is a potential biofuel with a greater energy content than bioethanol. Hydrogenation of HMF gives 2,5-bis(hydroxymethyl)furan. Acid-catalysed hydrolysis converts HMF into gamma-hydroxyvaleric acid and gamma-valerolactone, with loss of formic acid.
Ataxia with oculomotor apraxia type 1 (AOA1), also known as early-onset ataxia with ocular motor apraxia and hypoalbuminemia, is a rare autosomal recessive disorder caused by mutations in the APTX gene. AOA1 usually begins as uncoordinated movements and ataxia at the age of four but can start manifesting between ages two and ten. Also, they develop oculomotor apraxia, dysarthric speech, myoclonic jerks, chorea, cognitive impairment, and neuropathy. Elevated levels of cholesterol, creatine kinase, and decreased levels of albumin can be seen. Patients usually start using wheelchair after 11 years since the onset of the symptoms. APTX gene codes for the protein Aprataxin, which might help DNA repair by the removal of adenylate groups from 5′-phosphate terminus at single-strand DNA nicks and gaps. It is most common in Japan and Portugal.
=== Historiography === Anderson, Margaret Lavinia. "Confessions of a Fellow Traveler," Catholic Historical Review (2013) 99#4 pp 623–648. Drury, Marjule Anne. "Anti-Catholicism in Germany, Britain, and the United States: A review and critique of recent scholarship." Church History 70.1 (2001): 98-131 online Zeender, John K. "Recent Literature on the German Center Party," Catholic Historical Review (1984) 70#3 pp 428–441. in JSTOR
=== Non-phagocytic cells === In non-phagocytic cells, oxidative burst products are used in intracellular signalling pathways. The generated ROS achieve this via shifting the cell redox state. This may be monitored by the ratio of the antioxidant enzyme glutathione to its oxidised product, glutathione disulphide (GSH:GSSG). Antioxidant enzymes counterbalance redox signalling by eliminating the involved molecules, importantly superoxide anion and nitric oxide. Redox signalling is critical for normal processes such as proliferation, differentiation, as well as vascular function and neurotransmission. It is also involved in disease states such as cancer. The NADPH oxidase isoform NOX1 transiently produces a burst of superoxide in response to growth factor (e.g. EGF) stimulation of respective receptors. Superoxide is dismutated to hydrogen peroxide at a rate close to the diffusion-limited rate. This spatial restriction for superoxide‘s dismutation allows for specificity of redox signalling. Specificity is also ensured by NOX1 localisation in specific microdomains in the cell’s plasma membrane. Through channels such as aquaporin or diffusion, hydrogen peroxide enters the cytosol. There, it oxidises the cysteine groups of redox-sensitive proteins, which can then transduce signals.
Since the first preparation was reported in 1887, numerous synthetic routes to amphetamine have been developed. The most common route of both legal and illicit amphetamine synthesis employs a non-metal reduction known as the Leuckart reaction (method 1). In the first step, a reaction between phenylacetone and formamide, either using additional formic acid or formamide itself as a reducing agent, yields N-formylamphetamine. This intermediate is then hydrolyzed using hydrochloric acid, and subsequently basified, extracted with organic solvent, concentrated, and distilled to yield the free base. The free base is then dissolved in an organic solvent, sulfuric acid added, and amphetamine precipitates out as the sulfate salt. A number of chiral resolutions have been developed to separate the two enantiomers of amphetamine. For example, racemic amphetamine can be treated with d-tartaric acid to form a diastereoisomeric salt which is fractionally crystallized to yield dextroamphetamine. Chiral resolution remains the most economical method for obtaining optically pure amphetamine on a large scale. In addition, several enantioselective syntheses of amphetamine have been developed. In one example, optically pure (R)-1-phenyl-ethanamine is condensed with phenylacetone to yield a chiral Schiff base. In the key step, this intermediate is reduced by catalytic hydrogenation with a transfer of chirality to the carbon atom alpha to the amino group. Cleavage of the benzylic amine bond by hydrogenation yields optically pure dextroamphetamine.
Sources: en.wikipedia.org
amplification of the CCND1 gene / overexpression of cyclin D1; chromosomal translocation of the CCND1 gene; mutations in the degradation motif recognized by the CRL4-AMBRA1 E3 ubiquitin ligase; disruption of nuclear export and proteolysis of cyclin D1; induction of transcription by oncogenic Ras, Src, ErbB2 and STATs; Cyclin D1 overexpression is correlated with shorter cancer patient survival and increased metastasis. Amplification of the CCND1 gene is present in:
As with all amino acids, catabolism of lysine is initiated from the uptake of dietary lysine or from the breakdown of intracellular protein. Catabolism is also used as a means to control the intracellular concentration of free lysine and maintain a steady-state to prevent the toxic effects of excessive free lysine. There are several pathways involved in lysine catabolism but the most commonly used is the saccharopine pathway, which primarily takes place in the liver (and equivalent organs) in animals, specifically within the mitochondria. This is the reverse of the previously described AAA pathway. In animals and plants, the first two steps of the saccharopine pathway are catalysed by the bifunctional enzyme, α-aminoadipic semialdehyde synthase (AASS), which possess both lysine-ketoglutarate reductase (LKR) (E.C 1.5.1.8) and SDH activities, whereas in other organisms, such as bacteria and fungi, both of these enzymes are encoded by separate genes. The first step involves the LKR catalysed reduction of L-lysine in the presence of α-ketoglutarate to produce saccharopine, with NAD(P)H acting as a proton donor. Saccharopine then undergoes a dehydration reaction, catalysed by SDH in the presence of NAD+, to produce AAS and glutamate. AAS dehydrogenase (AASD) (E.C 1.2.1.31) then further dehydrates the molecule into AAA. Subsequently, PLP-AT catalyses the reverse reaction to that of the AAA biosynthesis pathway, resulting in AAA being converted to α-ketoadipate.
== Coupling with THG microscopy == Third-Harmonic Generation (THG) microscopy can be complementary to SHG microscopy, as it is sensitive to the transverse interfaces, and to the 3rd order nonlinear susceptibility
== Metabolism == As first discovered in 1882, pyroglutamic acid can be formed by heating glutamic acid at 180 °C, which results in the loss of a molecule of water. In living cells, it is derived from glutathione through the action of an enzyme, γ-glutamyl cyclotransferase. Pyroglutamic acid may function in glutamate storage, and acts to oppose the action of glutamate, including in the brain. It also acts on the brain's cholinergic system; Amyloid β containing pyroglutamic acid is increased in Alzheimer's disease; this may be part of the disease process. Increased levels of pyroglutamic acid in the blood, leading to excess in the urine (5-oxoprolinuria), can occur following paracetamol overdose, as well as in certain inborn errors of metabolism, causing high anion gap metabolic acidosis. Pyroglutamic acid is a natural humectant in skin, and part of its natural moisturizing factor (NMF). Pyroglutamic acid is also present as the N-terminal amino acid in orexin-A, a peptide involved in wakefulness, among other things.
Sources: en.wikipedia.org
The household was managed by a former naval quartermaster with the help of Black servants, and provisions were generally abundant except for flour. The initial weeks were spent testing scientific instruments and botanizing in the surrounding plains, astonished by the rapid growth and size of local vegetation. Humboldt noted the presence of plant species newly described by science, indicating the region’s botanical richness and the likelihood that many smaller plants remained undocumented. The scientific curiosity of the local population matched that of the visitors. The house became a destination for townspeople eager to observe scientific demonstrations, especially with the microscope, which fascinated Cumana's women. Humboldt reciprocated by attending local dances, learning both traditional and modern forms. Despite social distractions, Humboldt’s chief focus was meteorological observation, taking advantage of the region’s stable climate to collect data on atmospheric conditions. Humboldt’s house, situated on the main square, also exposed him to the realities of the local slave market. He was deeply disturbed by the sight of enslaved Africans being prepared for sale, their bodies oiled and inspected by buyers. While generally tolerant and patient in his dealings with others, Humboldt’s abhorrence of slavery was absolute. He could not accept rationalizations for the system, regardless of claims that Spanish slaves fared better than those elsewhere.
==== Fatal outcomes in case reports ==== A 2017 case report details the severe, prolonged episode of drug-induced parkinsonism in a 68‑year‑old man in the United States that ultimately led to his death roughly five months after receiving two injections of paliperidone palmitate (234 mg followed one week later by 156 mg). The authors state that "practitioners should be cognizant of the potential long‑term consequences of paliperidone LAI." A 47‑year‑old man (Japan, 2017) developed acute and persistent circulatory failure after receiving paliperidone palmitate injections. Despite surgical removal of the hip tissue suspected of containing the paliperidone palmitate depot, he died of multiple organ failure. When examining the removed tissue, it seemed that paliperidone palmitate was not present, and Janssen, the drug manufacturer, does not recommend this approach since it is practically impossible to locate the depot of paliperidone. The optimal treatment of long‐acting injectable (LAI) antipsychotic poisonings is unknown. In 2019, it was reported that a 33-year-old man in France was found dead in his room at his parents' home after receiving a single 819 mg injection of Trevicta (paliperidone palmitate three‑monthly formulation). Toxicological analysis of femoral blood revealed paliperidone at 240 μg/L; no other substance was detected. The authors concluded that paliperidone poisoning was the highly likely cause of death.
=== COVID-19 vaccine controversy === In February 2021, after a year long investigation relying on unnamed officials, Pfizer was accused by The Bureau of Investigative Journalism (TBIJ) of employing "high-level bullying" against at least two Latin American countries during negotiations to acquire COVID-19 vaccines, including requesting that the countries put sovereign assets as collateral for payments. According to TBIJ, these negotiation tactics resulted in a months long delay in Pfizer reaching a vaccine agreement with one country and a complete failure to reach agreements with two other countries, including Argentina and Brazil. In November 2021, TBMJ published an article after obtaining information from a whistleblower from the Ventavia Research Group. Ventavia was hired by Pfizer as a research subcontractor. A regional director (whistleblower) who was employed at Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer's pivotal phase III trial. The regional director, Brook Jackson, emailed a complaint to the FDA. Ventavia fired her later the same day. The European Medicines Agency (EMA) stated in a response to the European Parliament, that "the deficiencies identified do not jeopardize the quality and integrity of the data from the main Comirnaty trial and have no impact on the benefit-risk assessment or on the conclusions on the safety, effectiveness and quality of the vaccine".
=== National advisory and leadership roles === Eaton was elected to the Institute of Medicine (now the National Academy of Medicine) in 2011 and has led key national scientific committees. He presided over NASEM committees on the health effects of e-cigarettes (2018), dioxin exposure (2004–2006), and engineered nanoscale materials (2008). He led the 2018 cell phone radiation review panel, advised the NIEHS/NTP Director (2023–2024), and chaired the Board of Scientific Counselors (2020–2022) for the National Toxicology Program. He was Chair of the Health Effects Institute Research Committee (2010–2018) and President of the Society of Toxicology (2001–2002) and the Academy of Toxicological Sciences (2025–2026).
The first functionally characterized de novo gene identified in mice, a noncoding RNA gene, was also described in 2009. In primates, a 2008 informatic analysis estimated that 15/270 primate orphan genes had been formed de novo. A 2009 report identified the first three de novo human genes, one of which is a therapeutic target in chronic lymphocytic leukemia. This was, however, shown to lack sufficient evidence for translation and it is regarded as a lncrna. Since this time, a plethora of genome-level studies have identified large numbers of orphan genes in many organisms, although the extent to which they arose de novo, and the degree to which they can be deemed functional, remain debated.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide composed of nicotinamide, ribose, and phosphate. In cells, it is an intermediate in NAD+ biosynthesis.
No, NMN and NAD+ are different molecules. NMN is a precursor that cells can convert into NAD+ through enzymatic steps. NAD+ is a larger dinucleotide that serves as a coenzyme in many reactions.
Nicotinamide riboside, or NR, is another NAD+ precursor but has a different structure. NR lacks the phosphate group present in NMN. Both are studied for their roles in NAD+ metabolism, yet they enter cellular pathways in different ways.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ metabolism. It occurs naturally in cells and can also be produced synthetically for research or commercial use. Its name reflects its composition: nicotinamide, ribose, and a phosphate group.